Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.


Chemotherapy signatures

Nat. Genet. 51, 1732–1740 (2019)

Cancer therapies damage both cancerous tissues and healthy tissues, and the mutational signatures unique to each therapy informs understanding of their long-term side effects.

The DNA-damaging chemotherapies used as standard of care for most cancers are highly toxic and have serious long-term and delayed side effects. However, the burden of mutation induced by each therapy and how these unique signatures might influence adverse effects have not yet been explored in detail.

A group of European researchers analyzed data from 3,506 metastatic tumors treated with six anticancer agents: five chemotherapies and one radiotherapy. They developed a new analytical approach for identifying mutational signatures attributable to specific therapies and were able to predict the burden of these therapies, which in the future may be used to inform clinicians.

Author information



Corresponding author

Correspondence to Hannah Stower.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Stower, H. Chemotherapy signatures. Nat Med 26, 21 (2020).

Download citation


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing